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Background: The cause of almost all cases of Parkinson’s disease (PD) remains unknown. Recent years have seen
an explosion in the rate of discovery of genetic defects linked to PD. Different racial and geographical populations
may have different distributions of genetic variants.
Methods: In the current study, we screened the following genetic variants, including some rare mutations and
single nucleotide polymorphisms (SNPs), in a pedigree and cases-controls. To best of our knowledge, we first
screened these variants known to be associated with neurodegeneration disease, E46K (rs104893875) in SNCA,
A1442P in LRRK2, IVS9 in PARK2, A350V in SLC41A1, P268S (rs2066842), R702W (rs2066844), G908R (rs2066845), 1007fs
(rs2066847) in NOD2 and G2385R (rs34778348) in LRRK2 from southern China population. Genotyping was
performed by jointly using primers overlapping polymerase chain reaction (PCR) site-directed mutagenesis,
restriction fragment length polymorphism (RFLP), and capillary electrophoresis (CE).
Results: We didn’t discover above 9 variants in the family members of the pedigree. Furthermore, of 237 patients
with sporadic Parkinson’s disease and 190 controls, no heterozygosity or homozygosity were found from E46K,
A1442P, A350V, R702W, G908R, or 1007fs but heterozygosity onto G2385R, IVS9, and P268S. No significant difference
between cases and controls was found in both allele frequency (P = 0.572) and genotype frequency (P = 0.348) of
IVS9. However, significant differences in genotype frequency (P = 0.009) of G2385R were consistent with prior
observation. Eight patients with Parkinson’s disease (2 women and 6 men are over the age of 50 years at onset of
PD) carried the P268S heterozygous variation in NOD2. There was no heterozygosity or homozygosity of P268S in
the controls. Genotype frequency of P268S (P = 0.0450) had significant differences.
Conclusions: Our results suggested that the P268S variant in NOD2 might be a risk factor for susceptibility to
sporadic Parkinson’s disease in Chinese populations. It also implied that the inflammatory response may play a role
in PD.
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Parkinson’s disease (PD) is a complex neurodegenerative
disease caused by a variety of factors. The incidence in the
population over the age of 65 is about 1.8% [1]. The major
clinical features of PD include resting tremor, bradykinesia
and rigidity [2]. The pathological features of PD include pro-
gressive loss of dopaminergic neurons from the substantia* Correspondence: linqing2005602@aliyun.com; cmtzeng@xmu.edu.cn
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reproduction in any medium, provided the ornigra pars compacta and the presence of intercellular Lewy
bodies in surviving neurons [3]. The cause of PD is unclear,
but it is generally considered to be associated with the im-
pairment in degradation of ubiquitin proteasome system
(UPS), mitochondrial dysfunction, and oxidative stress [4-6].
We hypothesize that genetic and environmental factors and
aging together lead to the development of PD. In this study,
we investigated five genes, including SNCA, LRRK2, PARK2,
SLC41A1, and NOD2, all of which might be involved in the
cytological mechanisms of neurodegeneration disease aiming
to identify genetic variants associated with sporadic PD in
Chinese patients and understand the genetic etiology of PD.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SNCA (PARK1/4), which encodes α-synuclein. The major
mutations in SNCA include A53T, A30P, and E46K [7-9].
Although these mutations account for less than 1% of the
cases, patients carrying these mutations have obviously
clinical phenotypes [8]. The A53T and A30P mutations
have been found in Chinese patients with sporadic PD
[10]. However, the association of E46K with sporadic PD
has not been reported in Chinese patients.
LRRK2 (PARK8) encodes a large protein containing
five functional domains, involved in a number of
physiological functions, including substrate binding,
protein phosphorylation and protein interactions [11].
The most common mutation G2019 of LRRK2 in
European populations presents less than 0.1% in Asian
individuals [12]. The G2385R was at a significantly
higher frequency in Asian patients than in controls
[13]. One of the purposes of this study is to re-
validate this variant in southern China. In addition,
Yue Huang found A1442P in pedigrees of the Austra-
lian patients and considered it pathogenic, because it
is conserved across many species and a substitution of
Ala with Pro can change the secondary structure of
proteins [14]. However, A1442P has not been further
confirmed from a large number of cases and other
populations.
The most common cause of young-onset sporadic PD
is autosomal recessive PARK2 mutation [15]. The E3
ubiquitin ligase, parkin, which is encoded by PARK2, can
specifically degrade UPS through tagging ubiquitin on
protein [16]. Exon deletion, insertion, and point muta-
tions in PARK2 have been found in different ethnic
groups [17]. In 2009, Yih-Ru Wu screened 506 Taiwan
sporadic patients with age of onset below 50 years for
PARK2 gene mutation and identified a novel IVS9 inser-
tion (c.1084intron+) [18]. The c.1084intron+ was due to
a G > A polymorphism at position −6 of a cryptic splice
acceptor site within IVS9.
In recent years, genome-wide association studies
(GWAS) have identified a number of new susceptibility
loci associated with PD in different ethnic groups. Of
these loci, the most striking locus is PARK16, which is lo-
cated in 1q23 and contains 5 genes (SLC45A3, NUCKS1,
RAB7L1, SLC41A1, and PM20D1) [19]. SLC41A1 en-
codes a 56 kDa Mg2+ transporter consisting of 513 amino
acids, it has been proposed that PD might be associated
with lack of Ca2+ and Mg2+ in the brain [20]. In 2010,
Arianna Tucci sequenced PARK16 in 182 patients with
PD in the United Kingdom and found A350V in
SLC41A1, but failed to detect it in a large series of
ethnicity-matched controls (n = 483) [19]. To inspect
whether this coding mutations may or may not be the
disease-causing mutation, we aim to screen A350V in
Chinese Han populations.Several obtained findings suggest that inflammation
also contributes to the pathogenesis of PD [21-23]. It
has been reported that the G174C variant in the IL-6
promoter may influence the risk for developing PD, par-
ticularly regarding early age of onset PD [24]. Recent
studies revealed that NF-κB-mediated inflammation
might also play an important role in the pathogenesis of
PD [25,26]. NOD (nucleotide-binding oligomerization
domain) proteins, i.e. NOD1 (a product of CARD4 gene)
and NOD2 (encoded by NOD2), are intracellular signal-
ing molecules that recognize bacterial components, me-
diate the activation of NF-κB and induce or enhance
apoptosis [27]. In 2007, Monika Bialecka et al. screened
308 Portland patients for 3 variants (R702W, G908R,
and 1007fs) in NOD2 which were associated with
Crohn’s disease (CD) in Europeans. They found that
NOD2 might be associated with susceptibility to PD
[28]. Although inflammatory response has long been
considered as one of the factors for PD development, it
has not yet been reported that R702W, G908R, 1007fs
and P268S in NOD2 is associated with Chinese PD
patients.
In this study, we screened 237 patients with sporadic PD
and 190 controls for the 9 variants, E46K (rs104893875),
G2385R (rs34778348), A1442P, IVS9, A350V, R702W
(rs2066844), G908R (rs2066845), 1007fs (rs2066847) and
P268S (rs2066842), in 5 genes which are possibly found to
be associated with Chinese PD patients, including SNCA,
LRRK2, PARK2, SLC41A1, and NOD2. These variants in-
cluded both rare mutations (e.g. E46K and A1442P) and
SNPs, so we also screened them in a pedigree with two PD
cases. In this way, we aimed to provide references for the
study of disease-causing or susceptibility gene for PD. In
addition, using the overlap extension polymerase chain reac-
tion (PCR)-based site-directed mutagenesis, we constructed
wild-type and homozygous mutant plasmids for these vari-




A total of 237 sporadic patients with PD (94 women and
143 men) and a pedigree with two PD cases were recruited
from Xiamen First Hospital, Fujian Province, China. The
average age of enrollment was 60.3 ± 11.3, ranging from 25
to 83 years. Their average age of onset was 56.4 ± 10.8 years,
ranging from 23 to 80 years. Of these patients, 51 (21.5%)
had early-onset PD (EOPD), defined as the age at onset <50
years; 186 (78.5%) cases had late-onset PD (LOPD), with age
of onset ≥ 50 years. Patients were independently diagnosed
by two neurologists. Diagnostic criteria were taken from the
United Kingdom PD Brain Bank [29]. The severity of the
disease was determined using the Unified Parkinson’s Dis-
ease Rating Scale (UPDRS). The control group consisted of
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age of 51.7 ± 9.8 years (ranging from 23 to 80 years). The
cases and controls were matched with respect to age, gen-
der, and place of residence. This study was approved by the
Xiamen First Hospital Ethics Committee. Informed consent
was obtained from all participants.
Genomic DNA extraction
Five milliliters of peripheral blood with ethylene diamine
tetraacetic acid (EDTA) anticoagulant was collected from
each participant. Genomic DNA was extracted using the
MagCore Genomic DNA Whole Blood Kit and HF-16 ex-
tractor (Cat. No. MGB400-04, RBC Bioscience Taiwan)
according to the manufacturer’s instructions and stored all
samples at −20°C before use.
PCR amplification
Primers (Table 1) were designed using the software Pri-
mer Premier 5 according to the change of restriction
sites, caused by the mutation. Primers were synthesized
by Sangon Biotech (Shanghai, China).
Restriction endonuclease analysis
Target variants were detected using the PCR-RFLP
(restriction fragment length polymorphism) method.Table 1 Primer sequences, PCR conditions and restriction dig
Polymorphism Primer sequences (5′→ 3′) Annealing
temperature (°C)
E46K F: TGATGTGGGAACAAAGGGGA 58
R: GTGTTTCCTGAAATGCACTCTGA
A1442P F: GAGACTAAACTGCTGCTTGC 58
R: GTAATCTCGTATGGCAGGGA
A350V F: TCAGTGGTCTTTGCGTCATT 58
R: CTGTCCTTTTACTCTGCTCCC
P268S F: AGCCCATTGTCTGGTTAGGT 58
R: ACAGTGTCCGCATCGTCAT
R702W F: AGATCACAGCAGCCTTCC 63
R: CACGCTCTTGGCCTCACC















*: IVS9: Intervening sequence 9, PARK2.The digestion reaction and restriction enzyme digestion
conditions were taken from the manuals included with
the restriction enzymes purchased from the New England
BioLab (United States). Then 20 μl of digestion products
were loaded on 2% agarose gel containing ethidium brom-
ide, electrophoresed under 100 V for 30 min in 1× TAE,
and imaged using the gel imager. Digestion results of
homozygous mutants, heterozygous mutants, and wild-
type are shown in Table 1.
DNA sequencing
Based on the results from PCR-RFLP and site-directed
mutagenesis, the target fragments were re-amplified
using PCR. PCR products were purified using a DNA gel
purification kit, sequenced using the dideoxy four-color
fluorescence method on an automatic sequencer (ABI,
U.S.), and compared using GenBank data to confirm the
mutation sites.
Capillary electrophoresis (CE)
In this study, we initially established the test method
using CE to detect gene polymorphisms for PD. Briefly,
based on the susceptibility gene polymorphisms of PD
identified from PCR-RFLP, restriction fragments were







BsaJI 747 46E allele: 287,460
46K allele: 747
Hhal 801 1442A allele: 671,130
1442P allele: 801
MwoI 302 350A allele: 94,208
350V allele: 302
BamHI 309 268P allele: 309
268S allele: 225,84
MspI 185 702R allele: 20, 35, 54, 76
702W allele: 20, 35, 130
Hin6I 380 908G allele: 380
908R allele: 242, 138
ApaI 151 Wild type allele: 151
1007f allele: 130, 21
Xhol 775 Wild type allele: 318,457
IVS9 G→ A allele: 775
AccI 261 2385G:261
2385R:77,184
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silica capillary column with an inner diameter of 75 μl
and column length of 150 mm and Mops-Tris buffer of
pH 7.55. Then 0.5 μl of sample was electrically injected
in 4kV × 15 s at 25°C, electrophoresed at a constant volt-
age of 8 Kv, and detected for the laser-induced ethidium
bromide emission wavelength at 590 nm. The gel elec-
trophoresis profiles were compared to determine the
genotypes.
Statistical analysis
SPSS 18.0 (Statistical Package for the Social Sciences,
version 18.0 for Windows) was used for statistical ana-
lysis. Allele and genotype frequencies were compared
between cases and controls using the Fisher’s exact test.
To avoid multiple easily false, false discovery rate was
used to correct p values. Odds ratios and 95% confi-
dence intervals were calculated. A two-sided P value
≤0.05 was considered statistically significant. Power was




Figure 1 shows the pedigree (2 generations) of the family
that we studied. The age of PD onset for the affected in-
dividuals 3 and 4 in the kindred is 45 and 40, respect-
ively. We failed to discover any mutations of the 9
genetic variants, including rare mutations E46K and
A1442P originally found in the kindred. It may be
caused by low family members to detect the association.
Further studies using a larger Chinese pedigree with PD
patients are required to determine this.1 2
3 4
Figure 1 Pedigree of Parkinson’s disease (PD). Circle, woman;
square, man; filled square, affected.Case–control study
We analyzed 9 variants, E46K, G2385R, A1442P, IVS9,
A350V, P268S, R702W, G908R, and 1007fs in 237 spor-
adic patients with PD and 190 controls using the PCR-
RFLP and CE. All the genotypic and allelic distributions
analyzed in this study were in accordance with the
Hardy–Weinberg equilibrium. No heterozygosity or
homozygosity of E46K, A1442P, A350V, R702W, G908R,
or 1007fs was found. Heterozygosity of G2385R, IVS9,
and P268S were found in the case groups and controls
(Figure 2). The genotype frequency, allele frequency,
odds ratios, and confidence interval of these variants are
shown in Table 2.
The distribution of G2385R heterozygosity in LRRK2
was significantly different between cases and controls
(10.1% vs. 2.1%, P = 0.009). The intron IVS9 heterozy-
gous variant in PARK2 was found in both the case group
(12.7%) and the control group (7.9%). Although this vari-
ant had a higher frequency in the case group than the
control group, the difference was not statistically signifi-
cant (P = 0.348).
Although only 8 out of 237 patients were found to
carry the P268S heterozygous variant in NOD2, all these
patients (2 women and 6 men) had age at onset of over
50 years. Since no controls were found to carry this vari-
ant, the difference between cases and controls was
slightly significant (P = 0.0450). These results suggest
that the variant P268S in NOD2 might be associated
with late-onset PD and is one of the risk factors for
sporadic PD in Chinese Han populations.
Discussion
Gene polymorphism is a risk factor of PD, and it shows
different distributions in different ethnic groups and
geographies. Although GWAS have identified a number
of susceptibility genes and relevant variants associated
with PD in different populations, few of them have been
analyzed in other populations. To best of out knowledge,
we first screened 8 variants that have been associated
with neurodegeneration, E46K, A1442P, A350V, IVS9,
P268S, R702W, G908R, and 1007fs in Chinese popula-
tions, and further verified the presence of the high-
frequency variant G2385R in southern China.
In case–control study, both PD patients and controls
carried the heterozygous G2385R mutation, and the
genotype difference was slightly significant. This is con-
sistent with the results of a previous study of 600
Chinese PD patients and 334 controls [30]. This variant
was initially reported by Xingkai An. in 2008 among PD
patients in Sichuan area [30]. However, we did not find
E46K, A1442P, or A350V variants in patients with PD
and in controls. All of them indicated following
phenomenon: the ancestry effect; familial PD results
from rare, highly penetrant pathogenic mutation (e.g.
a c e
b d f
Figure 2 Capillary electrophoresis (CE) results of restriction fragments of 3 variants. a, c, e and b, d, f are the electropherograms and gel-
views of IVS9, P268S, and G2385R after restriction digestion, respectively. The green arrows indicate markers (20 bp, 1000 bp) and black arrows
indicate the restriction fragments. Restriction fragment sizes are shown in the Table 1: No mutation (wild-type/negative control), 2: Negative
results in the control group, 3: Positive results (heterozygote) in the case group, 4: Homozygous mutation (homozygote/positive control). Because
the signals are too strong for IVS9-4, P268S-1, P268S-2, G2385R-1, and G2385-2, 10 times markers are used to enhance the signal.
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A350V) contribute to the risk of PD and are involved in
the etiology of PD.
Interestingly, none of homozygosity of these variants
was found in either the case or control groups [31,32]. It
was reported that heterozygosity of autosomal recessive
genes was very important in the initiation and develop-
ment of PD. For example, it has been found that patients
with PD who carry heterozygous PARK2 and PINK1 mu-
tations have an age of onset between that of wild-type
individuals and patients with homozygous mutations
[33,34]. Heterozygous mutation carriers indeed show
preclinical changes at the metabolic, structural, or func-
tional levels that are detectable by modern techniques of
neuroimaging and electrophysiology. Heterozygosity for
putative recessive mutations could lead to disease expression
by at least three mechanisms which are haploinsuffciency,
dominant-negative effect and novel gain-of-function [35].
Taken together, heterozygous mutations in putative
recessive genes seem to increase the susceptibility to
develop PD.
The new insertion mutation, c.1084intron+ in PARK2,
introduces two new amino acids and a TAA stop codon,
resulting in reduced levels of parkin protein [36]. This
insertion mutation may be associated with the -6G > A
polymorphism of intron 9 in PARK2. One case–control
study found IVS9G > A to be a risk factor of PD in
Taiwan. A functional study of IVS9G > A by Guey-Jen
Lee-Chen showed that the shear efficiency of -6A wasslower than that of -6G at the protein level [37]. 12.7%
PD patients and 7.9% controls carried the heterozygous
IVS9 mutation, but the allele difference and genotype
difference were not statistically significant. This result is
consistent with the results of a previous study of 506
patients and 508 controls in Taiwan [18]. Further
investigation into the association between IVS9G > A
and PD need, through larger sample size from various
populations.
Inflammation is one of the suspected theories of PD.
The activation of NF-κB and microglial cells around
dopaminergic neurons have been analyzed in patients
with PD [38]. In 2007, Monika Bialecka reported that
three variants (R702W, G908R, and L1007fsinsC) of
NOD2 encoding NOD2, a protein that can activate the
apoptosis response, were significantly associated with
PD in a Polish population [28]. It has been demonstrated
that these three variants are not associated with CD in
Chinese Han, Korean, and Japanese populations [39-42].
Similarly, these three common SNPs (R702W, G908R,
and 1007fs) were not detected in our cohort. However, a
novel variant P268S was observed, which has also been
discovered to be associated with CD in Chinese popula-
tion [43]. Although linkage disequilibrium was observed
between P268S and the other three SNPs in NOD2, only
P268S of the four variants was slightly significant in our
study, which was consistent with recent study suggesting
that P268S instead of 1007fs, G908R, R702W was a risk
factor of Chinese Crohn’s disease population. It
Table 2 Genotype and allele frequencies of G2385R, P268S, and IVS9 in cases and controls
Genotype PD patients, n = 237 Control, n = 190 Odds ratio
(95% CI)*
p value** Power§
No. % No. %
G2385R(G > A)
GG 213 89.9 186 97.9 1
GA 24 10.1 4 2.1 5.24 0.009 0.8973
(1.79-15.38)
AA 0 0 0 0 — —
G 450 94.9 376 98.9 1
A 24 5.1 4 1.1 5.01 0.090 0.8803
(1.72-14.58)
P268S(C > T)
CC 229 96.6 190 100 1
CT 8 3.4 0 0 — 0.045 NA
TT 0 0 0 0 — —
C 466 98.3 380 100 1
T 8 1.7 0 0 — —
IVS9(G > A)
GG 207 87.3 175 92.1 1
GA 30 12.7 15 7.9 1.7 0.348 0.2987
(0.88-3.24)
AA 0 0 0 0 — —
G 444 365 96.1 1
A 30 6.3 15 3.9 1.64 0.572 0.2865
(0.87-3.10)
*: Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated by comparison to the common allele frequencies and genotype frequencies.
**: Fisher exact test and false discovery rate were used to calculate and correct the p values, respectively. Two sided P value ≤ 0.05 was considered
statistically significant.
§: Power was calculated by Power and Sample Size Calculations Version 3.0, 2009. NA: not available.
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in Chinese individuals, or the P268S variant may be in
linkage disequilibrium with another causal rare variant
on NOD2 gene. The frequencies of minor allele 1007fs,
G908R, R702W and P268S variants are much lower in
Asians compare to Caucasians populations. In this study,
genotype frequency of P268S (P = 0.0450) had slightly
significant differences. The sample size has to be very
large or odds ratio has to be very high to have enough
power for detection effect of very rare variants.
NOD2 is a member of the Apaf-1 superfamily of apop-
tosis regulators that is expressed in monocytes and
involved in the activation of NF-κB, by bacterial compo-
nent muramyl dipeptide (MDP) [44]. Functional studies
revealed that both normal and P268S NOD2 induced
similar levels of NF-κB activation in response to MDP
[45] and the G908R, R702W, and L1007fsinsC variants
in the presence and absence of P268S are defective in
their ability to respond to bacterial lipopolysaccharides
and peptidoglycan, whereas P268S alone exhibited wild-
type activity [46]. Thus, P268S was confirmed as thehaplotype background of these three variants but has no
influence on functions of the CD-associated variants of
NOD2 [47]. Notably, above results from NF-κB activa-
tion assay using human embryonic kidney (HEK) 293
cell lines, but the function activity of NOD2 in
neurodegeneration field remain unclear. Additionally,
Crane et al. found that carriage of the P268S variant was
associated with greater disease activity and inversely as-
sociated with ulcerative colitis spondylarthritis [48]. We
regarded the P268S of NOD2 behaving as a common
factor of PD and CD. Crohn’s disease is a chronic in-
flammatory disorder of the gastrointestinal tract, which
is thought to result from the effect of environmental
factors in a genetically predisposed host [49]. A wealth
of new information has emerged to suggest that
inflammation-derived oxidative stress and cytokine
dependent toxicity may contribute to nigrostriatal path-
way degeneration and hasten progression of disease in
humans with idiopathic PD. Both them suggest that
inflammation may play a role connecting between PD
and CD.
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We analyzed the genetic loci associated with PD in the
sporadic and family PD patients using PCR-RFLP and
found P268S might be a risk factor of sporadic PD in the
Chinese population. As it is the first study on NOD2
P268S in PD patients, the results should be treated with
caution, as one cannot completely exclude that they are
false positive. Further studies required to verify the asso-
ciation between P268S and susceptibility to sporadic
Parkinson’s disease in large sample size, and explore the
NOD2 functions involved in neurodegenerative diseases.
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